Full-Time

Lead – Field Engagement Operations Support

Deadline 9/24/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Power BI
Microsoft Office
Veeva
Six Sigma
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 10 years of progressive experience in commercial, sales, or marketing operations within a pharmaceutical, biotechnology, or equivalent organization is required.
  • Demonstrated experience applying business data analytics to generate actionable insights from complex, multi-source data sets is required.
  • Proven ability to deliver quality results consistently and maintain high standards is required.
  • A demonstrated track record of improving processes and driving efficiencies is required.
  • Experience growing processes and systems with increasing demand while maintaining quality is required.
  • A proven track record of sales force effectiveness support, promotional program design, or commercial operations is required.
  • Excellent stakeholder communication skills and the ability to influence without authority at all organizational levels are required.
  • Advanced proficiency in Microsoft Office Suite, including PowerPoint and Excel, Salesforce.com or Veeva, and reporting platforms such as Power BI and QlikSense is required.
  • Deep understanding of pharmaceutical compliance requirements, including Sunshine Act and transparency reporting, is required.
  • Strong interpersonal skills with demonstrated ability to train, coach, and develop others are required.
Responsibilities
  • Drive business partnerships with brand marketers, therapeutic area leads, medical teams, field sales, logistics vendors, compliance, and legal through regular Field Engagement Team interaction and meaningful insights.
  • Lead business review presentations and dashboard processes highlighting progress, trends, opportunities, risks, program volume, cost, and speaker and topic utilization.
  • Guide brands toward goal attainment by analyzing data, identifying trends, risks, and opportunities, and providing strategic recommendations.
  • Participate in and lead field champion calls, providing guidance and inquiry support.
  • Collaborate with Compliance, Legal, Veeva Events Support, vendors, and hub colleagues to address issues and ensure alignment.
  • Lead teams through transformation by modeling appropriate mindset and behaviors.
  • Drive annual speaker contract onboarding and Veeva Events go-live processes, including marketing kickoff, budget planning, speaker nomination and contracting, content and invitations, field configuration, and training coordination.
  • Serve as a subject matter expert for commercial and medical events systems, including Veeva, Salesforce.com, reporting platforms, nomination tools, and company policies.
  • Support project execution with timely responses to Veeva System counterparts and share knowledge with Field Engagement Operations teammates.
  • Use Power BI, budget, and events reporting to analyze reporting and explain details to stakeholders.
  • Use business data analytics to understand program performance, identify trends, and generate insights for improved decision-making.
  • Run ad hoc reports to support business needs and stakeholder requests.
  • Support business review processes and dashboards to ensure they meet business requirements and provide actionable insights.
  • Develop and maintain metrics and reporting environments using Veeva, Jira4Business, and Power BI.
  • Use artificial intelligence tools, automation platforms, and digital technologies to enhance productivity and generate data-driven insights.
  • Translate analytical findings into clear presentations for brand and sales leadership.
  • Create and maintain process flows and guidance documents to standardize operations and support knowledge transfer.
  • Review support and training documentation to ensure accuracy and relevance.
  • Identify inefficiencies, question existing processes, and implement solutions that optimize workflows and enhance performance.
  • Apply opportunity management discipline to prioritize activities and deploy resources against the highest-value opportunities.
  • Ensure programs are executed in full compliance with company policies and regulatory requirements.
Desired Qualifications
  • Direct experience supporting event management or speaker bureau programs in a pharmaceutical or biotechnology organization.
  • Proficiency with Veeva Events Management, Jira4Business, and Power BI.
  • Experience with artificial intelligence-powered analytics tools, automation platforms, or digital innovation initiatives.
  • Demonstrated project management success, including vendor relationships and cross-functional workstreams.
  • Certification in change management, process improvement methodologies such as Lean or Six Sigma, or digital transformation.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.